Processa Pharmaceuticals (PCSA) Interest Expenses (2012 - 2025)
Processa Pharmaceuticals' (PCSA) quarterly Interest Expenses came in at $18.0 in Q4 2025, down 99.51% on a QoQ basis from $3709.0 in Q3 2025.
Processa Pharmaceuticals (PCSA) Interest Expenses (2012 - 2025) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 14 years of Interest Expenses data on file, last reported at $18.0 in Q4 2025.
- Quarterly Interest Expenses changed N/A year-over-year to $18.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $201130.0 (changed N/A YoY) and the FY2025 annual result came in at $21.3 million, up 7.15% from the prior year.
- Interest Expenses eased to $18.0 in Q4 2025, from $3709.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $17.6 million in Q4 2023 to a low of $18.0 in Q4 2025.
- A 5-year average of $2.0 million and a median of $70040.0 in 2022 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2021 — Interest Expenses slumped 99.8% — and 2023, when it jumped 6304.58%.
- Tracing PCSA's Interest Expenses over 5 years: stood at $108558.0 in 2021, then surged by 13296.26% to $14.5 million in 2022, then increased by 21.29% to $17.6 million in 2023, then plunged by 99.47% to $93387.0 in 2024, then slumped by 99.98% to $18.0 in 2025.
- The last three Interest Expenses figures came in at $18.0 (Q4 2025), $3709.0 (Q3 2025), and $3920.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 82.05 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 20.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 93.62 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -4.89 Mn |
| 10 | Processa Pharmaceuticals | 5.93 Mn | 5.93 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 18.00 |
| Dec 31, 2025 | 18.00 |
| Sep 30, 2025 | 3,709.00 |
| Sep 30, 2025 | 3,709.00 |
| Jun 30, 2025 | 3,920.00 |
| Jun 30, 2025 | 3,920.00 |
| Sep 30, 2024 | 93,387.00 |
| Sep 30, 2024 | 93,387.00 |
| Jun 30, 2024 | 10,540.00 |
| Jun 30, 2024 | 10,540.00 |
| Mar 31, 2024 | 138,287.00 |
| Mar 31, 2024 | 138,287.00 |
| Dec 31, 2023 | 17.64 Mn |
| Dec 31, 2023 | 17.64 Mn |
| Sep 30, 2023 | 186,505.00 |
| Sep 30, 2023 | 186,505.00 |
| Jun 30, 2023 | 209,750.00 |
| Jun 30, 2023 | 209,750.00 |
| Mar 31, 2023 | 232,996.00 |
| Mar 31, 2023 | 232,996.00 |